128 related articles for article (PubMed ID: 22440786)
21. Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab.
Bersanelli M; Gnetti L; Azzoni C; Bottarelli L; Sverzellati N; Campanini N; Varotti E; Corrado M; Parziale R; Rapacchi E; Caruso G; Leonardi F; Silini EM; Buti S
Immunotherapy; 2018 Jul; 10(9):743-752. PubMed ID: 30008256
[TBL] [Abstract][Full Text] [Related]
22. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
[TBL] [Abstract][Full Text] [Related]
23. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
[TBL] [Abstract][Full Text] [Related]
25. Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
Porta C; Vercelli A; Paglino C
Eur Urol; 2014 Apr; 65(4):721-2. PubMed ID: 24007714
[No Abstract] [Full Text] [Related]
26. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
27. Temsirolimus for advanced renal-cell carcinoma.
Fazio N; Dettori M; Lorizzo K
N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17804854
[No Abstract] [Full Text] [Related]
28. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
Karam JA; Zhang XY; Tamboli P; Margulis V; Wang H; Abel EJ; Culp SH; Wood CG
Eur Urol; 2011 Apr; 59(4):619-28. PubMed ID: 21167632
[TBL] [Abstract][Full Text] [Related]
29. Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidence.
Khattak MA; Fisher RA; Pickering LM; Gore ME; Larkin JM
BJU Int; 2012 Nov; 110(10):1407-8. PubMed ID: 22937754
[No Abstract] [Full Text] [Related]
30. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
31. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
32. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.
Jilg CA; Neumann HP; Gläsker S; Schäfer O; Ardelt PU; Schwardt M; Schultze-Seemann W
Urol Int; 2012; 88(1):71-8. PubMed ID: 22156657
[TBL] [Abstract][Full Text] [Related]
33. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
Paterson C; Jones RJ
Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
[No Abstract] [Full Text] [Related]
34. Small bowel metastases from renal cell carcinoma: a rare cause of intestinal intussusception.
Roviello F; Caruso S; Moscovita Falzarano S; Marrelli D; Neri A; Rampone B; De Marco G; Perrotta ME; Mariani F
J Nephrol; 2006; 19(2):234-8. PubMed ID: 16736429
[TBL] [Abstract][Full Text] [Related]
35. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
36. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
[TBL] [Abstract][Full Text] [Related]
38. Lord of the rings: a promising novel treatment for renal cell carcinoma?
Johansson M
Eur Urol; 2011 May; 59(5):745-6. PubMed ID: 21276657
[No Abstract] [Full Text] [Related]
39. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization.
Moch H; Schraml P; Bubendorf L; Richter J; Gasser TC; Mihatsch MJ; Sauter G
Cancer Res; 1998 Jun; 58(11):2304-9. PubMed ID: 9622063
[TBL] [Abstract][Full Text] [Related]
40. Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.
Rizzo M; Facchini G; Savastano C; Di Lorenzo G; Lucia LD; Maiorino L; Casale B; Grimaldi G; Formato R; Febbraro A; Cartenì G
Future Oncol; 2015; 11(2):219-24. PubMed ID: 25078333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
